Covid-19 roundup: Squab­bles with gov­ern­ment de­lay Mod­er­na’s PhI­II — re­ports; No­vavax se­cures largest Warp Speed deal yet: $1.6B

A much-an­tic­i­pat­ed Phase III tri­al for Mod­er­na’s Covid-19 vac­cine is be­ing held up as the com­pa­ny de­layed sub­mit­ting tri­al pro­to­cols and sparred with gov­ern­ment sci­en­tists on how to run the study and even what the bench­mark for suc­cess should be, Reuters re­port­ed.

Mod­er­na, the first US com­pa­ny to put their vac­cine in­to hu­man test­ing, was sup­posed to en­ter a 30,000-per­son study this month in part­ner­ship with the NIH to de­ter­mine whether it can pre­vent in­fec­tion. STAT re­port­ed last week that the tri­al was fac­ing de­lays over the pro­to­col, but that a Ju­ly start was still pos­si­ble. Nei­ther the NIH nor Mod­er­na ever dis­closed a spe­cif­ic date the tri­al should start, but Reuters re­port­ed that the agency had hoped to be­gin on Ju­ly 10.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.